Skip to main content
Fig. 9 | Journal of Neuroinflammation

Fig. 9

From: Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling

Fig. 9

Nilotinib reduces LPS-mediated IL-1β, IL-6, and COX-2 mRNA and protein levels in wild-type mice. a–c Real-time PCR of IL-1β, IL-6, and COX-2 mRNA levels in the cortex and hippocampus (n = 8/group). d–f Immunofluorescence staining of IL-1β, IL-6, and COX-2 in brain slices from wild-type mice injected with vehicle (5% DMSO, 10% PEG and 20% Tween 80 in deionized water) or nilotinib (20 mg/kg, i.p.) daily for 7 days followed by LPS (10 mg/kg, i.p.) or PBS on day 7. The graphs present the quantification of the raw data from the IF staining in d–f (IL-1β, n = 14–20 brain slices from 3 to 4 mice/group: IL-6, and COX-2, n = 20–22 brain slices from 3 to 4 mice/group). g–i ELISA of IL-1β, IL-6, and COX-2 protein levels in the cortex and hippocampus (n = 8/group). *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar = 100 μM

Back to article page